Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 09, 2026
Why Is Paramount Skydance Corporation (PSKY) Stock Down -7.69% Today?

Why Is Paramount Skydance Corporation (PSKY) Stock Down -7.69% Today?

Key Takeaways

  • Paramount Skydance shares plunged 7.69% in intraday trading on Wednesday, falling to $9.00 from a previous close of $9.75.
  • Primary catalyst: Reports that multiple U.S. states are preparing to sue as early as next week to block the company's $110 billion acquisition of Warner Bros. Discovery.
  • Secondary driver: An ongoing probe by Oregon state regulators forced Paramount to delay the deal's closing until at least July 22, compounding uncertainty.
  • Broader context: The sell-off extends a multi-week downtrend for PSKY, which has now shed roughly 29% over the past six months amid persistent regulatory and integration concerns.
  • What traders are watching: Any official filing from state attorneys general, further updates from UK and EU competition authorities, and the company's upcoming Q2 earnings report expected around August 3.

Opening Summary

Shares of PSKY, the publicly traded Class B equity of Paramount Skydance Corporation — the global media and entertainment conglomerate formed through the merger of legacy Paramount Global and Skydance Media — tumbled sharply in Wednesday's session. The stock dropped 7.69% to trade at $9.00 as of early afternoon, extending losses from the prior session's close of $9.75. The sell-off was triggered by mounting regulatory headwinds surrounding the company's blockbuster bid to acquire WBD, with multiple U.S. states reportedly preparing legal action to block the transaction.

Regulatory Storm Clouds Gather Over Warner Bros. Discovery Deal

The dominant force behind Wednesday's decline was a cascade of negative headlines regarding Paramount Skydance's proposed $110 billion acquisition of Warner Bros. Discovery. Reuters reported that a coalition of U.S. states could file a lawsuit as early as next week seeking to block the merger on antitrust grounds. The news landed with particular force because it signals that opposition to the deal extends beyond federal regulators — who had already cleared the transaction — into state-level enforcement, introducing a new and unpredictable legal front.

Compounding the pressure, Paramount confirmed it would not close the Warner Bros. Discovery deal before July 22, citing an ongoing probe by Oregon state authorities. The delay, while procedural in nature, underscores the fragmented regulatory landscape the company must navigate. Each additional week of uncertainty raises questions about financing costs, integration timelines, and the risk that the deal's terms could be renegotiated or abandoned altogether.

International Scrutiny Adds to the Overhang

The regulatory challenges are not confined to the United States. The UK government has signaled it may challenge the acquisition over media plurality concerns, while European Union competition authorities are also reviewing the transaction. Although analysts have suggested the UK review may ultimately result in negotiated commitments rather than an outright veto, the cumulative weight of multi-jurisdictional scrutiny is weighing heavily on investor sentiment. The prospect of prolonged regulatory battles raises the risk that Paramount Skydance may be forced to divest assets or accept behavioral remedies that dilute the strategic rationale of the merger.

Sector Weakness and Broader Market Context

The sell-off in PSKY did not occur in isolation. The broader entertainment and media sector has faced persistent headwinds, with peers such as DIS, NFLX, and WBD also experiencing volatility as investors reassess the streaming landscape and the pace of cord-cutting. Paramount Skydance shares have been in a sustained downtrend, falling from a 52-week high of $20.86 to current levels near $9.00, reflecting deep skepticism about the company's ability to execute its ambitious consolidation strategy while managing a debt load that already exceeds $25 billion on an enterprise value basis.

Trading volume in Wednesday's session was elevated relative to the recent average, indicating that institutional investors were actively repositioning in response to the regulatory news. The stock broke below the psychologically significant $9.50 level and approached its 52-week low of $8.62, a technical breach that could trigger additional algorithmic selling if the decline persists.

Trending AI Robots

In volatile market environments like the one currently affecting media stocks, traders increasingly turn to automated strategies to navigate rapid price swings. Tickeron's Trending AI Robots page features a curated selection of AI-powered trading bots that have demonstrated strong performance under current market conditions. With hundreds of bots covering thousands of tickers — including PSKY — the platform highlights only those strategies that are currently outperforming. Bots vary by trading style, timeframe, performance metrics, and the symbols they trade, allowing users to identify approaches aligned with their objectives. Explore the Trending AI Robots page to see which strategies are gaining traction in today's market.

What Comes Next for PSKY

The immediate focus for PSKY shareholders centers on whether state attorneys general formally file a lawsuit in the coming days. Any such filing would likely trigger another leg lower, while a decision by states to hold off could spark a relief rally. Beyond the legal calendar, the company's next quarterly earnings report — estimated for early August — will be scrutinized for updates on the deal's financing structure, synergy targets, and the performance of the core streaming and linear television businesses.

Analyst sentiment remains cautious. Wells Fargo recently maintained an Underweight rating and lowered its price target to $7, reflecting concerns about execution risk and balance sheet leverage. The average analyst target sits at $12.64, but the wide dispersion between the low estimate of $7.00 and the high of $20.00 illustrates the profound uncertainty surrounding the stock. Key risks include further regulatory delays, deterioration in the linear TV advertising market, and the possibility that the Warner Bros. Discovery transaction collapses entirely, leaving Paramount Skydance to chart an independent path in an increasingly consolidated media landscape.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PSKY

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


PSKY's RSI Indicator recovers from overbought zone

The 10-day RSI Indicator for PSKY moved out of overbought territory on September 04, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 instances where the indicator moved out of the overbought zone. In 19 of the 21 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PSKY as a result. In 59 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.

The Moving Average Convergence Divergence Histogram (MACD) for PSKY turned negative on September 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 33 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.

PSKY moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PSKY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where PSKY advanced for three days, in 202 of 297 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.

PSKY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 71 of 129 cases where PSKY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. PSKY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.980) is normal, around the industry mean (18.508). PSKY has a moderately high P/E Ratio (371.000) as compared to the industry average of (97.633). Projected Growth (PEG Ratio) (1.158) is also within normal values, averaging (3.885). PSKY has a moderately high Dividend Yield (0.020) as compared to the industry average of (0.005). P/S Ratio (0.260) is also within normal values, averaging (2.913).

The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PSKY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock worse than average.

Notable companies

The most notable companies in this group are Netflix Inc. (NASDAQ:NFLX), Walt Disney Company (The) (NYSE:DIS), Roku (NASDAQ:ROKU), Paramount Skydance Corporation (NASDAQ:PSKY), AMC Entertainment Holdings (NYSE:AMC), iQIYI (NASDAQ:IQ), HUYA (NYSE:HUYA).

Industry description

Movies/entertainment industry include companies that produce and distribute motion pictures, and companies that operate general entertainment facilities like amusement parks and bowling centers. Some companies in this industry also have professional sports franchises. Live Nation Entertainment, Inc., Liberty Media Corp. and Viacom Inc. are some of the biggest companies in this space.

Market Cap

The average market capitalization across the Movies/Entertainment Industry is 17.55B. The market cap for tickers in the group ranges from 293 to 288.27B. NFLX holds the highest valuation in this group at 288.27B. The lowest valued company is BLMZF at 293.

High and low price notable news

The average weekly price growth across all stocks in the Movies/Entertainment Industry was -3%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was 0%. STRZ experienced the highest price growth at 7%, while CPOP experienced the biggest fall at -33%.

Volume

The average weekly volume growth across all stocks in the Movies/Entertainment Industry was 79%. For the same stocks of the Industry, the average monthly volume growth was 163% and the average quarterly volume growth was 102%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 65
P/E Growth Rating: 47
Price Growth Rating: 58
SMR Rating: 83
Profit Risk Rating: 76
Seasonality Score: 12 (-100 ... +100)
View a ticker or compare two or three
PSKY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a mass media company, which creates and distributes content across a variety of platforms to audiences around the world.

Industry MoviesEntertainment

Industry
N/A
Address
1515 Broadway
Phone
+1 212 258-6000
Employees
17600
Web
https://www.paramount.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.